Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation clinical trial (NCT05275374). Contact the study team or your healthcare provider for specific answers.

Question 2

How does XP-102 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation clinical trial (NCT05275374). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of XP-102 and trametinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation clinical trial (NCT05275374). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation clinical trial (NCT05275374). Contact the study team or your healthcare provider for specific answers.

Question 5

What will happen if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation clinical trial (NCT05275374). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation clinical trial (NCT05275374). Contact the study team or your healthcare provider for specific answers.

What this study is about